Changes in Medicaid GLP-1 Prescription Dispensing After 4 States Ended Weight-Management Coverage

Wait 5 sec.

On January 1, 2026, California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid coverage of GLP-1s indicated for weight management. In 2025 Q4 these four states accounted for 60.5% of Medicaid weight-management GLP-1 prescriptions nationally (661,478 of 1,094,191). We used State Drug Utilization Data from 2024 Q1 through 2026 Q1 to describe dispensing in the first quarter after withdrawal, classifying products by FDA-approved indication. In the withdrawing states, weight-management GLP-1 prescriptions were 1.06 per 100 enrollee-months in 2025 Q3, 1.08 in 2025 Q4, and 0.16 in 2026 Q1, a decline of 85%, while in six states that kept coverage the same figures were 0.90, 0.97, and 0.82. The difference-in-differences estimate was -0.67 (95% CI, -1.21 to -0.18). Gross reimbursement in the withdrawing states fell by $1,079 per 100 enrollee-months from 2025 Q3 to 2026 Q1. Dispensing of GLP-1s labeled for other indications did not rise: the estimate against 33 never-covering states was -0.03 (95% CI, -0.29 to 0.23), so increases larger than 0.23 per 100 enrollee-months, about one quarter of the weight-management decline, can be ruled out. Substitution toward diabetes-labeled products was at most limited in the first quarter after coverage ended.